Publication date: Sep 17, 2025
“Although it may have a small protective effect among higher-risk patients and on certain symptoms, the effect sizes are negligible,” the authors said. “Recent studies have found that nirmatrelvir-ritonavir is underutilized among older patients who are at risk of severe disease, despite the evidence of its benefits,” the authors concluded.
| Concepts | Keywords |
|---|---|
| Hospitalization | Ci |
| Negligible | Cohort |
| Summer | Covid |
| Found | |
| Long | |
| Older | |
| Patients | |
| Paxlovid | |
| Protective | |
| Reduction | |
| Risk | |
| Severe | |
| Small | |
| Treated | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | death |
| disease | IDO | symptom |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Nonoxynol-9 |
| disease | MESH | long COVID |
| disease | MESH | infections |
| disease | MESH | complications |
| disease | MESH | COVID-19 |
| drug | DRUGBANK | Ritonavir |
Original Article
(Visited 6 times, 1 visits today)